secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-039304
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion reports Q4 2023 net loss $34.9M; cash $177.2M; clinical data readouts expected 2024
--------------------------------------------------------------------------------

- Net loss $117.3M for FY 2023 vs $81.8M in 2022; Q4 loss $34.9M vs $25.3M.
- Cash, equivalents, restricted cash, investments $177.2M at Dec 31, 2023, up from $113.4M year earlier.
- R&D expenses $102.5M for FY 2023, up from $62.7M, driven by BMF-219 and BMF-500 clinical costs.
- Phase 2 type 2 diabetes data showed continued glycemic control 5 months off therapy; expansion cohort of 216 patients underway.
- Phase 2 type 1 diabetes study (COVALENT-112) initiated; initial data readout anticipated in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/0000950170-24-039304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000095017024039304/bmea-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-039304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer